Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
The Japanese government on August 2 approved KM Biologics’ freeze-dried smallpox vaccine LC16 “KMB” for an additional indication for the prevention of monkeypox. The green light comes days after the label expansion gained the backing of the Pharmaceutical Affairs and…
To read the full story
Related Article
- MHLW Reports 1st Mpox Death in Japan, Man in 30s
December 14, 2023
- MHLW Starts Clinical Study on Mpox Vaccine for People with High Infection Risks
June 19, 2023
- Mpox Cases Hit 120 in Japan: MHLW
April 27, 2023
- Number of Mpox Cases Totals 109 in Japan: MHLW
April 17, 2023
- Mpox Cases Top 100 in Japan, 10 New Patients Confirmed
April 13, 2023
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
- Japan Detects 2nd Monkeypox Case in Tokyo
July 29, 2022
- KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
July 25, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Up for MHLW Panel Review on July 29
July 19, 2022
- Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
REGULATORY
- MFN Now a Factor in Japan’s Drug Pricing Debate: New Pharma Policy Chief
September 11, 2026
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
- Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
- OTC-Like Drug Charge Gets Prescription Field; No Double Charge with LLP Rule
September 10, 2026
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…